Clinical trials: Dermatofibrosarcoma Protuberans (DFSP)
Dermatofibrosarcomas of DARIER FERRAND(DFSP)
Phase II Pazopanib Study in Advanced Dermatofibrosarcomas
In relation to the activation of PDGF-mediated signalization due to the fusion gene COL1A1-PDGFb in DFSP, imatinib (800mg/day) has shown activity in advanced DFSP and has became the reference treatment option for these patients.
- Trial name
- DFSP-PAZO (NCT01059656)
- Testing
- Pazopanib
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Skin Neoplasms, Carcinoma, Basal Cell
Spanish Registry of Mohs Surgery
REGESMOHS (Registro Español de cirugía de Mohs) aims at describing effectiveness of Mohs surgery, and patient, tumor and technique factors related to adverse events and tumor recurrence.
- Conditions
- Skin Neoplasms, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Dermatofibrosarcoma
- Trial name
- REGESMOHS (NCT02310503)
- Testing
- Mohs surgery
- Where
- 15 sites in Spain
- Volunteers
- 6,000 people
- Sponsor
- Fundación Academia Española de Dermatología
Cancer
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).
- Trial name
- PALANGI3 (NCT01046487)
- Testing
- Imatinib mesylate, Cyclophosphamide (Dosing level 1 ), Imatinib mesylate, Cyclophosphamide (Dosing level 2), Imatinib mesylate, Cyclophosphamide (Dosing level 3)
- Where
- 3 sites in France
- Volunteers
- 26 people
- Sponsor
- Centre Oscar Lambret